डेनमार्क - डेनिश - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - olanzapin - smeltetabletter - 10 mg

डेनमार्क - डेनिश - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - olanzapin - smeltetabletter - 15 mg

डेनमार्क - डेनिश - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - olanzapin - smeltetabletter - 20 mg

यूरोपीय संघ - डेनिश - EMA (European Medicines Agency)

ucb pharma s.a. - romosozumab - osteoporose - narkotika til behandling af knoglesygdomme - evenity er indiceret til behandling af svær osteoporose hos postmenopausale kvinder med høj risiko for knoglebrud.

डेनमार्क - डेनिश - Lægemiddelstyrelsen (Danish Medicines Agency)

industrial farmacéutica cantabria, s.a. - clobetasolpropionat - shampoo - 500 mikrogram/g

यूरोपीय संघ - डेनिश - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

डेनमार्क - डेनिश - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - lenograstim - pulver og solvens til injektions- /infusionsvæske, opløsning - 33,6 mill. ie

डेनमार्क - डेनिश - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - clobetasolpropionat - shampoo - 500 mikrogram/g

डेनमार्क - डेनिश - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - clobetasolpropionat - shampoo - 500 mikrogram/g

यूरोपीय संघ - डेनिश - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.